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Ovarian cancer is the leading cause of death from gynaecological
malignancies in the US (Parker et al, 1996) and occurs with
highest frequency in Northern and Western Europe and North
America (Whelan et al, 1992). Five-year survival rates for patients
with stage III disease are approximately 15–20%, and less than 5%
for patients with stage IV disease (NIH Consensus Statement,
1994). The diagnosis of ovarian disease at an advanced tumour
stage hinders the prospects of survival and cure. The majority of
patients respond well to platinum-based therapies, but most subse-
quently relapse and develop progressive disease. Although early
diagnosis is a primary goal, secondary aims are to identify those
patients with borderline and early stage tumours who will rapidly
progress and develop metastatic disease. A marker of such prog-
nostic value could identify those patients who may benefit from
aggressive therapy.
The primary mediator of cAMP events in eukaryotes is the
cAMP-dependent protein kinase (PKA) (Walsh et al, 1968), which
is composed of an inactive tetramer containing two regulatory (R)
subunits associated as a dimer and two catalytic subunits (C).
There are two types of PKA, type I and type II, which contain the
same C subunit but differ in the R subunit they contain (RI and RII
respectively) (Reimann et al, 1971). Evidence suggests that over-
expression of the type I PKA is associated with proliferation
and cell transformation (Cho-Chung, 1990), therefore type I RI
isoforms are thought to induce cell growth. Conversely, low
expression of type I PKA (with or without alterations in the level
of RII isoforms) correlates with terminal differentiation and
growth inhibition (Cho-Chung, 1993). The mammalian ovary is
under constant stimulation by pituitary gonadotropins, luteinizing
hormone (LH) and follicle-stimulating hormone (FSH), which
modulate the expression of numerous gonadal genes and exert
their effects by activating cAMP synthesis through adenylate
cyclase (Land, 1987). In view of the role of type I PKA in the
regulation of cellular growth and differentiation, we have specu-
lated that dysregulation of the PKA pathway may have profound
effects on ovarian pathology. In this study, we have evaluated the
expression of the RIa subunit of the type I cAMP-dependent
protein kinase (PKA) in patients with ovarian cancer and in human
ovarian cancer cell lines.
MATERIALS AND METHODS
Cell culture
All ovarian cell lines were derived from serous cystadenocarci-
nomas of the ovary, except for the OTN14 cell line which was
derived from a mucinous cystadenocarcinoma. The PEA1 and
PEA2 ovarian cell lines were kindly provided by Dr S Langdon
(Langdon et al, 1988). OTN14 was kindly provided by Dr L Poels
(Van Niekerk et al, 1988), OAW42 cells from Dr A Wilson
(Wilson, 1984) and A2780 cells from Dr RI Freshney. All cell lines
were maintained in RPMI (GibcoBRL) supplemented with 10%
heat-inactivated fetal calf serum (Imperial), penicillin–strepto-
mycin (100 mg ml–1), sodium pyruvate (100 mg ml–1) and insulin
(10 mg ml–1) in a humidified 5% carbon dioxide atmosphere.
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Summary The primary element in the cAMP signal transduction pathway is the cAMP-dependent protein kinase (PKA). Expression of the RIa
subunit of type I PKA is elevated in a variety of human tumours and cancer cell lines. The purpose of this study was to assess the prognostic
importance of RIa expression in patients with ovarian cancer. We have evaluated the expression of RIa in a panel of human ovarian tumours
(n = 40) and five human ovarian cancer cell lines using quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western
blot analysis. The human ovarian cell lines OAW42 and OTN14 express high endogenous levels of RIa mRNA and protein (at significantly
higher mRNA levels than high tissue expressors, P < 0.05). The ovarian cell line A2780 expresses low endogenous levels of RIa mRNA and
protein (also at higher mRNA levels than low tissue expressors, P < 0.05). Quantitative RT-PCR revealed no significant difference in RIa
mRNA expression between different ovarian histological subtypes in this study. No associations were found between RIa mRNA expression
and differentiation state. RIa mRNA expression was significantly associated with tumour stage (P = 0.0036), and this remained significant
in univariate analysis (P = 0.0002). A trend emerged between RIa mRNA expression levels and overall survival in univariate analysis
(P = 0.051), however, by multivariate analysis, stage remained the major determinant of overall survival (P = 0.0001). This study indicates
that in ovarian epithelial tumours high RIa mRNA expression is associated with advanced stage disease. RIa expression may be of predictive
value in ovarian cancer and may be associated with dysfunctional signalling pathways in this cancer type.
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Tissue samples from patients with suspected ovarian epithelial
carcinoma were collected at initial debulking surgery. Samples
were stored in liquid nitrogen upon collection and transferred to
vials for long-term storage at –70°C, or in vials suspended in liquid
nitrogen. Clinicopathological details, such as histology, grade and
differentiation state were determined by an ovarian pathologist and
retained on a computer database for future reference.
RNA extraction
Cells (107) were lysed by passing through a fine needle and
syringe in 0.5–1 ml of Total RNA Isolation Reagent (Advanced
Biotechnologies), followed by chloroform extraction and precipi-
tation according to the manufacturer’s instructions. The isolation
procedure extracted DNA and proteins into an organic phase and
interphase which was discarded, eliminating the need for DNAase
treatment before polymerase chain reaction (PCR). Negative PCR
controls containing RNA instead of cDNA confirmed the absence
of contaminating genomic DNA. Approximately 100 mg of tissue
samples were homogenized (Ultra-turrax T8, IKA laboratories,
Germany) in 1 ml of isolation reagent at 4°C. Pelleted RNA was
resuspended in DNAase-RNAase-free distilled water (Sigma) and
quantified by measuring absorbance at 260 and 280 nm (LKB
Ultraspec II). Samples were also electrophoresed on 1% agarose
gels containing ethidium bromide (10 mg ml–1) to verify sample
integrity and the exclusion of genomic DNA. RNA was stored
at –70°C.
Quantitative reverse transcription polymerase chain
reaction (RT-PCR)
Total RNA (5 mg) was reverse transcribed in a 50-ml reaction
volume containing 300 U of MMLV reverse transcriptase
(GibcoBRL) in the presence of oligo(dT) at a final concentration
of 0.02 mg ml–1 (Pharmacia Biotech), 60 U RNAguard (Pharmacia
Biotech), 0.5 mM dNTPs, 10 mM DTT and 1 ´ RT buffer at 37°C
for 1 h, followed by 95°C for 5 min. All reactions used DNAase-/
RNAase-free distilled water and cDNAs were stored at –70°C.
The gene for the S14 ribosomal protein was used as an internal
standard for quantification of RIa mRNA (Leonard et al, 1993)
(accession number M13934). S14 primers amplify a fragment of
143 bp from cDNA. S14HumS sense strand (nucleotides
187–208): 5¢-GGC AGA CCG AGA TGA ATC ATA A-3¢.
S14HumA antisense strand (nucleotides 331–311):5¢-CAG GTC
CAG GGG TCT TGG TCC-3¢.
RIa primers were designed as areas of minimal homology with
other R isoforms and yield an amplicon of 338 bp with cDNA.
This fragment codes entirely for mRNA, which is translated into
protein (accession no M33336).
RIaP1 sense strand (nucleotides 648–667): 5¢-AAA GAA TGG
GCA ACC AGT G-3¢. RIaP2 antisense strand (nucleotides
986–976): 5¢-GCT GAC CCC TCT AAA ATA ATG-3¢. All primer
sets were manufactured by R & D systems, UK. Expression of RIa
mRNA was described as a ratio of S14 expression levels.
cDNA (2 ml) was amplified in an 18-ml PCR mix containing
0.25 U Taq DNA polymerase, 1.5 mM magnesium chloride and
1  ´ Taq buffer (all Thermoprime Plus, Advanced Biotech-
nologies), 1 mM S14HumA, S14HumS, RIaP1 and RIaP2, and
2.5 mCi [32P]-dCTP (3000 Ci mmol–1). Thermocycling was carried
out on a Perkin Elmer Cetus 480: after an initial melt at 94°C for
4 min, samples were amplified through 18 cycles of 94°C for
1 min, 54°C for 2 min and 72°C for 30 s, with a final incubation at
72°C for 5 min. The linear range of amplification was established
at 18 cycles. Samples were amplified in duplicate and PCR products
were denatured at 95°C and electrophoresed on 6% polyacry-
lamide gels (Ultragel Sequagel Complete, National Diagnostics).
Gels were dried at 80°C for 40 min (Rapidry-electrophoresis
ATTO, Japan) and exposed to radiographic film in a cassette with
intensifying screens at –70°C for a period of 24–96 h. Radio-
labelled products were analysed using a densitometer (Bio-rad
GS670, Molecular Analyst software).
Optimization of RT-PCR
The series of cell lines described earlier were used to optimize the
assay conditions. PCR standardization was found to be an impor-
tant factor in obtaining reliable results, and extensive validations
of the technique with regard to reproducibility and PCR amplifica-
tion efficiency were carried out. Cycle optimization determined
the linear range of amplification to be 18 cycles (assuming a stan-
dard cDNA concentration of 5 mg and taking into account the vari-
ability in RIa mRNA expression in the cell lines). Reproducibility
was achieved by preparing all reactions from a ‘master mix’ of
appropriate reagents. Negative controls were routinely included by
amplifying blanks containing distilled water, and genomic DNA,
to verify primer specificity and amplicon size. Exposure times of
dried gels were monitored and analysis ratios for which S14 values
exceeded 6.0 were excluded in the calculation of the overall value.
Western blot analysis
Cell pellets were sonicated in 50–200 ml of 0.1 M KPhos lysis
buffer, pH 7.4 (1 M potassium dihydrogen phosphate:1 M dipotas-
sium hydrogen phosphate; 4:1) in the presence of protease
inhibitors (0.1 mM phenylmethylsulphonyl fluoride, 3.3 mg  ml–1
aprotinin and 10 mg ml–1 leupeptin). Lysates were centrifuged at
14 000 r.p.m. for 5 min at 4°C to remove cell debris and the super-
natent recovered to fresh tubes. Total protein was quantified
against a bovine serum albumin standard using the method of
Bradford (1976). Equal quantities of protein (10–100 mg) were
resolved on 7.5–10% polyacrylamide gels using the Mini-
PROTEAN II electrophoresis cell and transfer system (Bio-rad).
Ten microlitres of prestained sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE) high-range standards
(Bio-rad) was also loaded onto gels to determine optimal electro-
phoretic separation of proteins. Proteins were transferred for 2 h in
transfer buffer (48 mM Tris, 39 mM glycine and 0.5 M EDTA in
20% methanol). Nitrocellulose blots were incubated for 30 min at
room temperature in blocking solution [phosphate-buffered saline
(PBS)/0.1% Tween/5% blocking agent]. Filters were washed three
times in PBS/0.1% Tween, and incubated with a 1:1000 dilution
of anti-protein kinase A RIa monoclonal antibody (Transduction
Laboratories, UK) in PBS/0.1% Tween/5% block overnight at 4°C
(or at room temperature for 1 h). Blots were washed three times in
PBS/0.1% Tween and secondary antibody applied [anti-mouse
horseradish peroxidase conjugated (Amersham, UK)] at a 1:2000
dilution at room temperature for 1 h in PBS/0.1% Tween/5%
block. Blots were washed three times in PBS/0.1% Tween. The
chemiluminescent substrate based on the enhanced chemilumines-
cence (ECL) method of Amersham was applied to blots for 1 min.
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exposed to radiographic film for periods of between 10 s and 1 h.
The size of detected proteins was estimated by comparison with
the location of prestained standards on the blot. Quantitative
analysis was carried out by densitometry. Blots were subsequently
stripped by immersing in buffer (1 M glycine hydrochloride,
pH 2.8, 4 M sodium chloride) at room temperature for 1 h followed
by three washes with copious volumes of PBS/0.1% Tween, before
reprobing with an anti-a-tubulin mouse monoclonal antibody
(Sigma, UK) at 1:1000 dilution in PBS/0.1% Tween/2.5% block.
Expression of RIa protein was described as a ratio of a-tubulin
expression levels, and the cell line PEA1 was assigned a relative
value of 1.0.
Statistical analysis
The mean RIa:S14 ratios and the relationships between variables
were analysed using non-parametric statistical tests (Mann–Whitney
U-test, Kruskal–Wallis) using the software SPSS. Cox regression
models were used to evaluate the relationship between RIa mRNA
expression and clinical features of each tumour. These models were
used to test whether overall survival was independent of prognostic
factors (stage, grade and histology). All P-values are two-sided.
Overall survival times were calculated from the date of first surgery
to death.
RESULTS
Expression of RIa mRNA and protein in six human
cancer cell lines
Quantifiable levels of RIa mRNA were detected in all five cell
lines (mean RIa mRNA expression = 0.161 ± 0.104) with a 4.8-
fold difference in RIa mRNA expression ratios between the
highest and lowest expressors, OAW42 and A2780 respectively
(Figure 1). RIa mRNA expression was highest in the cell line
OAW42 (mean RIa mRNA expression = 0.295) and lowest in the
cell lines A2780 and PEA1 (mean RIa mRNA expression =
0.055). The cell lines PEA2 and OTN14 also expressed high levels
of RIa mRNA. Mann–Whitney U-test analysis of the data
confirms a significant difference in the RIa mRNA expression
levels of OAW42 cells (high expressors) compared with A2780
and PEA1 (low expressors) (P < 0.05, n = 5).
RIa protein levels were determined using a monoclonal antibody
(Figure 2) (mean RIa protein expression = 0.847 ± 0.584). The cell
lines A2780 and PEA2 expressed the lowest endogenous levels of
RIa protein, whereas OAW42 cells expressed the highest levels.
RIa protein expression was also relatively high for the cell lines
PEA1 and OTN14. The levels of RIa mRNA and protein expres-
sion are consistent with respect to the cell lines A2780, OAW42
and OTN14, however there is an inverse relationship between RIa
mRNA and protein expression in the cell lines PEA1 and PEA2
and, therefore, a poor statistical correlation in a comparison of all
cell lines (r2 = 0.266; P > 0.5). In a comparison of cell line data,
excluding PEA1 and PEA2, there is a good statistical correlation
between RIa mRNA and protein expression levels (r2 = 0.932).
Moreover, in a preliminary investigation of RIa protein expression
levels in the tumours examined, there was also a good correlation
between RIa mRNA and protein expression levels (r2 = 0.86).
Expression of RIa mRNA in human ovarian epithelial
tissue
Quantifiable levels of RIa mRNA were detected in all tumours:
serous, n = 15; mucinous, n = 14; endometroid, n = 7; clear cell,
RIa expression in ovarian cancer 935
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Figure 1 (A) Autoradiograph showing RIa and S14 mRNA expression
levels in the five cell lines. Samples were amplified in duplicate. 
(B) Composite graph depicting the average distribution of RIa mRNA levels
in five ovarian cancer cell lines (± s.e.)
Figure 2 (A) Autoradiograph depicting RIa and a-tubulin protein expression
in the five cell lines. (B) Composite graph depicting the average distribution of
RIa protein in the cell lines (± s.e.). Each protein value is standardized against
the value obtained for PEA1, which is assigned an arbitrary value of 1.0n = 4. RIa mRNA was detectable at low levels in one benign
serous tumour. Unfortunately, the number of benign and border-
line ovarian tumours were underrepresented in this study because
of poor availability. Expression ratios were found to vary exten-
sively among samples with a 1192-fold difference in RIa expres-
sion between the highest and lowest expressors (ratios ranging
from 0.0002 to 0.2384), and data was skewed towards the lower
levels. RIa mRNA expression levels were divided into two malig-
nant groups for the analysis of survival data, RIa high (n = 15)
compared with RIa low (n = 16), based on expression levels
below and above the median RIa mRNA expression level.
Histopathological correlations
There was a trend for higher RIa mRNA expression levels in
malignant ovarian tumours than benign and borderline tumours,
however, this was not significant (P = 0.0871) (Figure 3; Table 1).
The pooled median RIa mRNA expression levels for serous
tumours was 0.058 ± 0.0224, for mucinous tumours 0.0227 ±
0.006, for endometrioid tumours 0.035 ± 0.012 and for clear cell
tumours 0.023 ± 0.031. There was also a trend for serous tumours
to express higher levels of RIa mRNA than mucinous tumours,
however this difference was not significant (P = 0.068) nor were
there significant statistical differences in RIa mRNA expression
of all histological subtypes (P = 0.201) (Figure 4). Figure 5A and
B depicts the RT-PCR autoradiographs obtained from serous and
mucinous tumour histologies respectively.
No significant difference was detected between RIa mRNA
expression levels of well/moderately and poorly differentiated
tumours of all histological subgroups (P = 0.568), nor was any
association observed in a subset analysis of serous and mucinous
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Figure 3 RIa mRNA expression levels in malignant, borderline and benign
ovarian tumours. No significant differences were observed between tumour
groups. Horizontal bars, median values
Figure 4 RIa mRNA expression levels in histological subtypes of malignant
ovarian tumours. No significant differences were observed between tumour
histologies. Horizontal bars, median values
Figure 5 Levels of RIa and control S14 mRNA expression in (A) serous
and (B) mucinous ovarian tumours after RT-PCR for 18 cycles as described
in Materials and methods
Table 1 Association of RIa mRNA expression with clinicopathological
features
Variable Classification P-value
Pathology Benign 0.0871*
Borderline
Malignant
Histology Serous 0.201*
Mucinous
Endometrioid
Clear cell
Histology Serous 0.0683**
Mucinous
Stage Benign 0.0036*
Borderline
Stage I/II
Stage III/IV
Stage Stage I/II 0.001**
Stage III/IV
Differentiation state Well/moderate 0.568*
Poor
*Kruskal–Wallis test; **Mann–Whitney U-test.
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Btumour grades. Tumour grade was not associated with RIa mRNA
expression in ovarian tumours. Univariate analysis of grade and
histological subtype (for serous and mucinous only) indicated
significant associations with overall survival (P = 0.0375 and
P = 0.0205 respectively).
Relationship to tumour stage
RIa mRNA expression levels were highest in stage III and IV
tumours (n = 17; median RIa mRNA expression = 0.041 ± 0.0628),
regardless of histology, and lowest in benign, borderline and stage I
and II ovarian tumours (n = 23; median RIa mRNA expression =
0.0151 ± 0.0322). These differences were true for all histological
types (P= 0.0036; Figure 6). This significance increases in a compar-
ison of stage I/II with stage III/IV tumours (P = 0.001). Therefore,
regardless of histology, increased RIamRNA expression was associ-
ated with advanced stage ovarian tumours. The association of RIa
mRNA expression with tumour stage remains significant in an
analysis of serous and mucinous histologies individually (P < 0.01).
Clinical associations
The median survival time for RIa low mRNA expressors was 142
weeks compared with 60 weeks for the RIa high subgroup (Figure
7). Log-rank analysis of the data indicated a trend between RIa
mRNA expression levels and overall survival by univariant
analysis (P = 0.051), however this is lost by multivariate analysis
(Table 2).
Cox models were used to evaluate the association of RIa
mRNA expression with overall survival, controlling for the clin-
ical parameters of histology, stage and grade (Table 2). Tumour
stage had the most significant statistical association with overall
survival (P = 0.0002, univariate analysis). Moreover, by multi-
variate analysis, stage remained significant (P = 0.0001–0.0002),
RIa expression in ovarian cancer 937
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Figure 6 RIa mRNA expression levels measured relative to S14 mRNA
expression in benign, borderline, stage I, II, III and IV ovarian tumours.
There is a significant difference between the medians of each subgroup
(P = 0.0036), and between the medians of stage I/II and stage III/IV tumours
(P = 0.001). Horizontal bars, median values
Figure 7 Association of RIa mRNA expression with overall survival in
patients with ovarian cancer. This relationship has a trend towards statistical
significance, with patients expressing higher levels of RIa mRNA exhibiting
shorter overall survival rates. Low RIa expressor: number of cases = 16,
number of events = 11; high RIa expressor: number of cases = 15, number of
events = 13
Table 2 Significance levels from Cox models to test for the association of RIa mRNA expression with overall survival controlling for other prognostic factors
Variable Classification RIa low (n)R I a high (n) Univariate P-value*
Histology Serous 3 8 0.737
Mucinous 5 4
Endometrioid 3 4
Clear cell 2 2
Histology Serous 3 8 0.0205
Mucinous 5 4
Stage Benign 3 2 0.0002
Borderline 4 0
Stage I/II 10 4
Stage III/IV 3 14
Differentiation state Well/moderate 7 6 0.0375
Poor 6 10
RIa status Low n = 16 – 0.051
High n = 15 –
*Log-rank statistic based on Cox models. RIa mRNA expression divided into two categories, RIa high/RIa low, which correspond to values below and above the
median value.after adjusting for RIa mRNA status, histology and grade. Thus,
although RIa expression is associated with stage and survival,
tumour stage was the most significant predictor of survival in this
cohort.
DISCUSSION
In this study, we have examined the expression of RIa in patients
with ovarian cancer. The results indicate that elevated levels of
RIa mRNA show a very significant correlation with advanced
stage ovarian cancer (P = 0.0036). There was no statistically
significant relationship between RIa mRNA expression and
patient survival. However, there was a trend towards this, in which
those patients whose tumours expressed lower levels of RIa
mRNA expression had longer overall survival rates (P = 0.051).
In contrast to this study, an analysis of PKA binding proteins
from 107 human ovarian tumours suggests that both total cAMP-
binding protein levels and photoaffinity-labelled RI protein levels
were not significantly associated with stage (P > 0.5) (Simpson
et al, 1996). Given the poor correlation between RIa mRNA and
protein found with our panel of cell lines, this may provide a
possible explanation for the different findings of both studies. The
findings presented here underline the potential role of the RIa
subunit overexpression with respect to advanced tumour stage and
subsequent poor prognosis. The accurate determination of the
prognostic significance of RIa mRNA expression will require a
prospective study utilizing large-sample analysis.
RIa overexpression may also be useful as a tool for monitoring
disease progression and response to treatment. Unfortunately,
there was only a small number of matched pairs available in our
ovarian tumour bank which did not reveal a significant trend. A
more extensive study of RIa expression in breast cancer patients
after treatment with tamoxifen has been reported (Miller et al,
1996). From the 37 matched tumour pairs available, decreases in
RIa expression levels were observed in 18 patients, increases in
ten patients, and no change in RIa status in nine patients.
Seventeen of the 18 patients with decreased levels of RIa expres-
sion showed tumour regression, indicating that RIa expression
may have potential as a prognosticator of clinical response.
Current therapeutic strategies which target PKA include the cAMP
analogue 8-Cl-cAMP, which is currently in phase I/II clinical trial
(Tortora et al, 1995), and RIa antisense oligonucleotides
(Nesterova et al, 1995). Both approaches involve the modulation
of endogenous PKA I/II intracellular ratios via the down-regula-
tion of RI isoforms. Because endogenous expression levels of RIa
determine the concentration of 8-Cl-cAMP required to induce
growth inhibition (McDaid et al, 1997), the future therapeutic effi-
cacy of both may rely on the determination of endogenous RIa
expression levels in patients who are most likely to benefit from
PKA-targeted treatment.
In this study, RIa mRNA expression was not associated with
tumour pathology or grade and we did not find statistically signifi-
cant differences between the RIamRNA expression levels of serous
compared with mucinous, endometrioid or clear cell tumours,
although a trend was apparent for serous tumours to express higher
levels of RIa mRNA. Simpson et al (1996) have found an associa-
tion between elevated RI protein and the serous histological
subgroup (P = 0.01). The consequence of elevated levels of RIa
expression for serous tumours would be a relative up-regulation of
PKAI activity compared with PKAII activity, but, overall, a
decrease in free catalytic subunits and a subsequent reduction in
phosphorylation of proteins by this pathway. Because it is believed
that the cAMP pathway generally antagonizes the growth factor-
stimulated pathway (Beebe, 1994), this decrease in downstream
signalling by the cAMP pathway may remove this inhibition and so
promote cell proliferation in an already dysfunctional cell.
This study has also addressed the expression of RIa mRNA in a
panel of ovarian cell lines. Endogenous RIa in these ovarian cell
lines can be divided into two categories, low expressors (PEA1
and A2780), which express at levels comparable to those found in
tissue samples expressing high levels, and high expressors (PEA2,
OAW42 and OTN14), whose expression greatly exceeds levels
determined in all tissue samples (P < 0.05). One simple observa-
tion for the difference in expression levels between the two groups
is a difference in the DNA content of the cells. The two low
expressors, PEA1 and A2780, have pseudodiploid modal chromo-
some numbers of between 41 and 50 whereas those cell lines
which displayed greatly elevated levels of RIa have modal
chromosome numbers of ³ 80, therefore gene amplification may
explain this observation.
In conclusion, the level of RIa mRNA expression is associated
with advanced stage ovarian cancer, but not with overall survival,
although there is a trend by univariate analysis between high levels
of RIa mRNA expression and poor patient survival. A prospective
study exploiting larger sample numbers will be necessary to fully
evaluate the role of RIa as a prognosticator of survival.
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